Inicio>>MCP110

MCP110

Catalog No.GC61032

MCP110 es un inhibidor de la interacciÓn Ras/Raf-1. MCP110 bloquea la interacciÓn de Ras con Raf. MCP110 interrumpe esta interacciÓn y podrÍa usarse para la investigaciÓn de tumores humanos.

Products are for research use only. Not for human use. We do not sell to patients.

MCP110 Chemical Structure

Cas No.: 521310-51-0

Tamaño Precio Disponibilidad Cantidad
5mg
185,00 $
Disponible
10mg
324,00 $
Disponible
50mg
881,00 $
Disponible
100mg
1.251,00 $
Disponible

Tel:(909) 407-4943 Email: sales@glpbio.com

Reseñas de cliente

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

MCP110 is an inhibitor of Ras/Raf-1 interaction. MCP110 blocks the interaction of Ras with Raf. MCP110 disrupts this interaction might can be used for the research of human tumors[1].

MCP110 (10 and 20 uM) inhibits H-Ras (V12)-induced AP-1 activation in HEK293 cells. Ras stimulation of Raf-1 activity is significantly decreased by MCP110 (20 μM) [1].MCP110 (1, 2, 5, 10, and 20 μM) shows a dose-dependent inhibition of elevated Raf-1 activity in fibrosarcoma HT1080 cells[1].MCP110 (20 μM) decreases cyclin D level stimulated by the treatment with EGF (100 ng/mL), platelet-derived growth factor (20 ng/mL) , serum, or phorbol 12-myristate 13-acetate (100 nM) in A549 cells[1].

[1]. Juran Kato-Stankiewicz,et al. Inhibitors of Ras/Raf-1 Interaction Identified by Two-Hybrid Screening Revert Ras-dependent Transformation Phenotypes in Human Cancer Cells. Proc Natl Acad Sci U S A. 2002 Oct 29;99(22):14398-403.

Reseñas

Review for MCP110

Average Rating: 5 ★★★★★ (Based on Reviews and 18 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for MCP110

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.